Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/181687PREPARATION METHOD FOR AND INTERMEDIATE OF DRUG-LINKER FOR ANTIBODY DRUG CONJUGATE MC-MMAF
WO 17.09.2020
Int.Class C07K 5/062
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
062the side chain of the first amino acid being acyclic, e.g. Gly, Ala
Appl.No PCT/CN2019/092950 Applicant LEVENA BIOPHARMA CO., LTD. Inventor XU, Zhe
A preparation method for and an intermediate of a drug-linker for an antibody drug conjugate MC-MMAF. The reaction activity of the N-terminus is improved, so that the occurrence of a racemic reaction is effectively controlled. The toxin MMAF is not directly used and a fragment peptide having low toxicity is used, so that an operation difficulty in mass production is reduced. No reverse-phase preparation is required so that the operations are simple.
2.WO/2020/181837METHOD FOR RESCUING INFLUENZA VIRUS AND COMPOSITION THEREFOR
WO 17.09.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2019/121905 Applicant ZHEJIANG SENWEI BIOPHARMACEUTICAL DEVELOPMENT CO., LTD. Inventor DAI, Dongsheng
Provided are a new method for rescuing an influenza virus and a composition therefor. The method comprises providing a host cell stably integrated with and expressing influenza virus PA, PB1, PB2 and NP genes, and introducing an influenza virus rescue system in which a stop codon is introduced into the PA, PB1, PB2 and NP genes respectively into the host cell to achieve virus rescue. The produced virus particles can be used as a live attenuated influenza vaccine, which is characterized in that, since the genes encoding the related proteins are mutated, it has no replication and proliferation ability in human and normal animal cells, and replication and proliferation can be achieved only in the host cells constructed above and it can fully stimulate the body immunity and effectively protect the body while ensuring the safety.
3.WO/2020/182077USE OF GLI2 INHIBITOR AND METHOD FOR SCREENING COMPOUND INHIBITING GLI2
WO 17.09.2020
Int.Class C07C 405/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
405Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
Appl.No PCT/CN2020/078224 Applicant INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES Inventor WANG, Yu
A prostaglandin as represented by formula I and an analog thereof used as medicines, and a pharmaceutical composition containing the compounds, particularly used as an inhibitor of zinc finger domain-containing protein GLI2 (i.e., glioma-associated oncogene-2), and used for treatment, prevention, or alleviation of tumors (particularly tumor resistance) in subjects, or neurodegenerative diseases or developmental syndromes and malformations caused by dysregulation of signaling pathways involving GLI2. Also provided is a method for screening a compound inhibiting GLI2.
4.WO/2020/182197LIQUID COMPOSITION COMPRISING ANTIBODY OF HUMAN INTERLEUKIN-4 RECEPTOR ALPHA
WO 17.09.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/079120 Applicant SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. Inventor ZHENG, Wei
The present invention provides a liquid composition comprising an antibody of human interleukin-4 receptor alpha. The liquid composition comprises the antibody at a concentration of 50-200 mg/ml; and a buffer, a protectant, and a surfactant as adjuvants. The liquid composition has a pH of 5.4-6.4.
5.WO/2020/182227PREPARATION METHOD FOR HIGH PURITY LIRAGLUTIDE SIDE CHAIN
WO 17.09.2020
Int.Class C07D 207/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
46with hetero atoms directly attached to the ring nitrogen atom
Appl.No PCT/CN2020/088481 Applicant AMPHASTAR NANJING PHARMACEUTICALS,INC. Inventor CHENG, Lihua
Disclosed is a preparation method for high purity liraglutide side chain, comprising: using palmitic acid, N-hydroxysuccinimide and N,N’-diisopropylcarbodiimide as reaction starting materials, and sequentially obtaining Palmitoyl-OSu, Palmitoyl-Glu-OtBu and liraglutide side chain crude product Palmitoyl-Glu(OSu)-OtBu; filtering the reaction solution, washing the resulting filtrate with an acidic aqueous solution, and concentrating the organic phase until dry; recrystallizing the organic phase with an alkane, a fatty alcohol or a mixed solvent thereof to obtain high purity liraglutide side chain. The preparation method for high purity liraglutide side chain has a simple operation, a short synthesis cycle, low costs and easy post-processing, the product purity can reach up to 99.41%, and HOSU, DIU, myristic acid, L5-S2 and stearic acid impurities, as well as other unknown impurities, can be effectively removed, which is beneficial for mass production.
6.WO/2020/182577PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
WO 17.09.2020
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/EP2020/055724 Applicant SYNGENTA CROP PROTECTION AG Inventor KOLLETH KRIEGER, Amandine
Compounds of the formula (I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling animal pests, including arthropods and in particular insects, nematodes, molluscs or representatives of the order Acarina.
7.WO/2020/182587STERICALLY HINDERED AMINE STABILIZER MIXTURES
WO 17.09.2020
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Appl.No PCT/EP2020/055754 Applicant BASF SE Inventor VITALI, Manuele
The present invention relates to mixtures of sterically hindered amines of the formulae (1 ) and (2) wherein at least one of the radicals Z1, Z2, Z3, Z4, Z5 and Z6 is C1-C18 alkyloxy or C5-C7 cycloalkyloxy and the remaining of the radicals Z1, Z2, Z3, Z4, Z5 and Z6 are hydrogen, hydroxy, C1-C18 alkyloxy or C5-C7 cycloalkyloxy, and at least one of the radicals Y1, Y2, Y3, Y4, Y5 and Y6 is a group of formula -CH2-CH=CH-R and the remaining of the radicals Y1, Y2, Y3, Y4, Y5 and Y6 are hydrogen or a group of formula -CH2-CH=CH-R, and the other substituents are as defined according to the present invention, methods for stabilization of an organic material, and a process for the preparation of compounds of formula (1').
8.WO/2020/182857TRANSCRIPTION FACTOR-MEDIATED PROMOTION OF DIRECT SOMATIC EMBRYOGENESIS
WO 17.09.2020
Int.Class A01H 4/00
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
HNEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
4Plant reproduction by tissue culture techniques
Appl.No PCT/EP2020/056457 Applicant PERPETUUM CROPSCIENCE BVBA Inventor HOFENK, Jeroen
A recombinant protein for use in a liquid culture medium for photo-autotrophic micropropagation of Cannabis Sativa L. is disclosed. The recombinant protein comprises a fusion of a growth induction part and a uptake enhancement part. The growth induction part comprises an Arabinogalactan protein and/or a plant transcription factor associated with plant growth and development. The uptake enhancement part comprises a cell penetrating peptide sequence and a nuclear localization signal encoded by the peptide sequence SEQ ID NO 1.
9.WO/2020/183147IMMUNOTHERAPY COMBINED WITH AN ANTI-CD38 ANTIBODY
WO 17.09.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/GB2020/050567 Applicant AUTOLUS LIMITED Inventor PEDDAREDDIGARI, Vijay
The present invention relates to the use of an anti-CD38 antibody in a subject undergoing immunotherapy wherein the anti-CD38 antibody is administered before and/or after immunotherapy.
10.WO/2020/183307DIHYDRO-SPIRO[INDOLINE-3:1'-ISOQUINOLIN]-2-ONES AND THEIR ANALOGUES AND DERIVATIVES AND METHODS OF TREATING CANCER AND OTHER DISEASES
WO 17.09.2020
Int.Class C07D 471/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
Appl.No PCT/IB2020/051930 Applicant THE UNIVERSITY OF BUEA Inventor MABANYI, Lobe Maloba Mesembe
The present invention is directed to various 3',4'-dihydro-2'H-spiro[indoline-3:1'-isoquinolin]-2-one compounds and methods for treating disease states and/or conditions which are mediated through sphingosine-1-phosphate receptor(s). The present invention is also directed to the use of these compounds as anticancer agents and as modulators of sphingosine-1-phosphate receptor function in the treatment of disease states and/or conditions which are mediated through these receptors. In addition, the invention relates to pharmaceutical compositions comprising one or more of these compounds alone or in combination with other therapeutic agents. The invention is also directed to methods of treatment of cancer and/or conditions that may respond to the modulation of sphingosine-1-phospate receptor function and which employ compounds of the present invention or pharmaceutical compositions comprising one or more of the compounds of this invention.